

February 26, 2015

## GlycoMimetics to Present at Two Investor Conferences in March

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that members of its executive team will present in March at two investor conferences, as follows:

- President & CEO Rachel King will present at the Cowen & Co. 35th Annual Healthcare Conference, The Boston Marriott Copley Place, Boston, on March 2, 2015, at 2:10 p.m. ET. The company will also participate in a breakout session at 2:50 p.m. ET that day.
- Ms. King will participate in a plenary session panel at the Bio-Europe Spring® 2015 Conference, Paris, France, on March 9, 2015, at 10:45 a.m. DT.

To access the live webcast and subsequent archived recordings for the presentation at the Cowen conference, please visit the GlycoMimetics website at <a href="https://www.glycomimetics.com">www.glycomimetics.com</a>.

## About GlycoMimetics, Inc.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics entered into an exclusive license agreement with Pfizer for rivipansel in October 2011. Under the license agreement, Pfizer is responsible for the clinical development, regulatory approval and potential commercialization of rivipansel.

A GlycoMimetics wholly-owned candidate therapy (GMI-1271) for acute myeloid leukemia (AML) and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at <a href="https://www.glycomimetics.com">www.glycomimetics.com</a>.

GlycoMimetics Brian Hahn, 240-243-1207 bhahn@glycomimetics.com

Source: GlycoMimetics, Inc.

News Provided by Acquire Media